Panacea Acquisition Stock Quote NUVB - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

2.76

Bid

Ask

Volume

328,164

2.74 Day's Range 2.84

0.95 52 Week Range 4.1598

Market Cap

687.917M

Previous Close

2.80

Open

2.84

Last Trade

2.7573

Last Trade Time

11:06:47

Financial Volume

$ 913,585

VWAP

2.7839

Average Volume (3m)

1,485,144

Shares Outstanding

249,245,129

Dividend Yield

PE Ratio

-9.14

Earnings Per Share (EPS)

-0.3

Revenue

Net Profit

-75.8M

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of t... Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

ecor1cap.com

Headquarters

Wilmington, Delaware, USA

Founded

Panacea Acquisition Corp is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker NUVB. The last closing price for Panacea Acquisition was $2.80. Over the last year, Panacea Acquisition shares have traded in a share price range of $ 0.95 to $ 4.1598.

Panacea Acquisition currently has 249,245,129 shares outstanding. The market capitalization of Panacea Acquisition is $697.89 million. Panacea Acquisition has a price to earnings ratio (PE ratio) of -9.14.

Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024

Tumors shrank in 89% of taletrectinib-treated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who were tyrosine kinase inhibitor (TKI)-naïve and 56% of those who...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.26	-8.60927152318	3.02	3.155	2.74	1653961	2.9404889	CS
4	-0.19	-6.4406779661	2.95	3.3986	2.74	1503994	3.01805389	CS
12	-0.25	-8.30564784053	3.01	3.97	2.625	1485144	3.10586622	CS
26	0.815	41.9023136247	1.945	4.1598	1.67	1674716	3.12065519	CS
52	1.41	104.444444444	1.35	4.1598	0.95	1365745	2.47069752	CS
156	-6.5	-70.1943844492	9.26	10.45	0.95	980542	3.36438547	CS
260	-7.24	-72.4	10	15.23	0.95	957517	4.52311985	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AMPXAmprius Technologies Inc	$ 1.07 (20.36%)	2.33M
MPLNChurchill Capital Corp III	$ 8.78 (16.69%)	111.05k
FEDUFour Seasons Education Cayman Inc	$ 10.21 (15.76%)	7.71k
DNMRDanimer Scientific Inc	$ 0.3686 (13.42%)	300.12k
GPMTGranite Point Mortgage Trust Inc	$ 3.215 (13.20%)	381.22k
MNSOMINISO Group Holding Limited	$ 14.185 (-13.82%)	7.05M
SESSES AI Corporation	$ 0.6769 (-11.03%)	1.63M
PNSTPinstripes Holdings Inc	$ 0.80913 (-9.23%)	25.49k
EVTLVertical Aerospace Ltd	$ 6.01 (-8.94%)	40.48k
KEPKorea Electric Power Corporation	$ 7.55 (-8.04%)	82.71k
PLTRPalantir Technologies Inc	$ 37.49 (0.78%)	33.18M
NIONIO Inc	$ 5.476 (3.71%)	31.66M
SWNSouthwestern Energy	$ 6.8949 (2.60%)	12.31M
FFord Motor Company	$ 10.7706 (-1.01%)	12.16M
BABAAlibaba Group Holding Limited	$ 90.72 (2.75%)	10.84M